EP4117668A4 - Composition et méthode de traitement oral de la leucémie - Google Patents

Composition et méthode de traitement oral de la leucémie Download PDF

Info

Publication number: EP4117668A4
Authority: EP; European Patent Office
Prior art keywords: leukemia; composition; oral treatment; oral; treatment
Prior art date: 2021-04-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP21935450.3A

Other languages

German (de)

English (en)

Other versions

EP4117668A1 (fr

Inventor

Aru NARENDRAN

Dominic Rodrigues

Bruce Horowitz

Edward V. PERSHING

Eric A. Wachter

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

UTI LP

Provectus Pharmatech Inc

Original Assignee

UTI LP

Provectus Pharmatech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-04-16

Filing date

2021-04-16

Publication date

2023-12-06

2021-04-16 Application filed by UTI LP, Provectus Pharmatech Inc filed Critical UTI LP

2023-01-18 Publication of EP4117668A1 publication Critical patent/EP4117668A1/fr

2023-12-06 Publication of EP4117668A4 publication Critical patent/EP4117668A4/fr

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Hematology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EP21935450.3A 2021-04-16 2021-04-16 Composition et méthode de traitement oral de la leucémie Pending EP4117668A4 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2021/027702 WO2022220841A1 (fr)	2021-04-16	2021-04-16	Composition et méthode de traitement oral de la leucémie

Publications (2)

Publication Number	Publication Date
EP4117668A1 EP4117668A1 (fr)	2023-01-18
EP4117668A4 true EP4117668A4 (fr)	2023-12-06

Family

ID=83640921

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21935450.3A Pending EP4117668A4 (fr)	2021-04-16	2021-04-16	Composition et méthode de traitement oral de la leucémie

Country Status (8)

Country	Link
EP (1)	EP4117668A4 (fr)
JP (1)	JP7525638B2 (fr)
KR (1)	KR20230171854A (fr)
CN (1)	CN115955969A (fr)
AU (1)	AU2021440597A1 (fr)
CA (1)	CA3175637A1 (fr)
MX (1)	MX2022012945A (fr)
WO (1)	WO2022220841A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002005812A1 (fr) *	2000-07-14	2002-01-24	Photogen, Inc.	Medicaments pour le traitement chimiotherapeutique de maladies
KR20070022308A (ko) *	2004-05-10	2007-02-26	로버트 에프 호프만	암 치료용 약제학적 조성물
US20190350893A1 (en) *	2018-05-16	2019-11-21	Provectus Pharmatech, Inc.	In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010081173A2 (fr) *	2009-01-12	2010-07-15	Cytomx Therapeutics, Llc	Compositions d’anticorps modifiées et leurs procédés de production et d’utilisation
US8765725B2 (en) *	2012-05-08	2014-07-01	Aciex Therapeutics, Inc.	Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2018047917A1 (fr) *	2016-09-09	2018-03-15	国立大学法人東京大学	Effet antitumoral synergétique d'une combinaison de la protéine hmg, de l'anticorps anti-cd4 ou d'un agent de contrôle de point de contrôle immunitaire
AU2018251788B2 (en) *	2017-04-12	2025-04-10	Aura Biosciences, Inc.	Targeted combination therapy
EP3612181A4 (fr) *	2017-04-21	2021-01-06	Epizyme, Inc.	Thérapies d'association avec des inhibiteurs d'ehmt2

2021
- 2021-04-16 CA CA3175637A patent/CA3175637A1/fr active Pending
- 2021-04-16 KR KR1020227039851A patent/KR20230171854A/ko active Pending
- 2021-04-16 EP EP21935450.3A patent/EP4117668A4/fr active Pending
- 2021-04-16 JP JP2022562946A patent/JP7525638B2/ja active Active
- 2021-04-16 WO PCT/US2021/027702 patent/WO2022220841A1/fr not_active Ceased
- 2021-04-16 MX MX2022012945A patent/MX2022012945A/es unknown
- 2021-04-16 CN CN202180038959.2A patent/CN115955969A/zh active Pending
- 2021-04-16 AU AU2021440597A patent/AU2021440597A1/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002005812A1 (fr) *	2000-07-14	2002-01-24	Photogen, Inc.	Medicaments pour le traitement chimiotherapeutique de maladies
KR20070022308A (ko) *	2004-05-10	2007-02-26	로버트 에프 호프만	암 치료용 약제학적 조성물
US20190350893A1 (en) *	2018-05-16	2019-11-21	Provectus Pharmatech, Inc.	In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PROVECTUS PRESS RELEASE: "Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Oral Administration of Rose Bengal Disodium for Cancer Treatment - Provectus Biopharmaceuticals, Inc.", 13 August 2020 (2020-08-13), XP093309861, Retrieved from the Internet <URL:https://www.provectusbio.com/news/press-releases/provectus-pr-20200813-1/> *
See also references of WO2022220841A1 *
SWIFT LUCY ET AL: "In Vitro Activity and Target Modulation of PV-10 Against Relapsed and Refractory Pediatric Leukemia", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 132, 29 November 2018 (2018-11-29), pages 5207, XP086592718, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2018-99-119438 *

Also Published As

Publication number	Publication date
EP4117668A1 (fr)	2023-01-18
AU2021440597A1 (en)	2022-11-10
JP7525638B2 (ja)	2024-07-30
MX2022012945A (es)	2023-03-16
WO2022220841A1 (fr)	2022-10-20
JP2023529262A (ja)	2023-07-10
CN115955969A (zh)	2023-04-11
KR20230171854A (ko)	2023-12-21
CA3175637A1 (fr)	2022-10-20

Publication	Publication Date	Title
EP4182026A4 (fr)	2024-10-02	Composition à base de cannabidiol (cbd) et méthode de traitement de la douleur
EP4121077A4 (fr)	2024-06-19	Compositions et méthodes de traitement de tumeurs solides et molles et de maladies prolifératives
EP4247357A4 (fr)	2024-09-25	Méthode de traitement de la maladie de parkinson
EP4319751A4 (fr)	2025-02-26	Compositions thérapeutiques et méthodes de traitement de tumeurs
EP3886862A4 (fr)	2022-10-26	Composition et procédé de traitement de la démence
EP4308732A4 (fr)	2025-02-26	Méthodes de classification et de traitement de patients
EP4387627A4 (fr)	2025-06-11	Méthode et compositions de traitement d'infections virales animales
EP4210753A4 (fr)	2025-01-08	Méthode de traitement de l'amylose
EP4292596A4 (fr)	2025-03-19	Méthode et combinaison pour le traitement de tumeurs
EP4326277A4 (fr)	2025-03-26	Méthodes de traitement de strictions d'sophagiennes
EP4135760A4 (fr)	2024-04-17	Compositions et méthodes de traitement de la leucémie
EP4275808A4 (fr)	2024-12-25	Procédé de traitement de plaque arrière et plaque arrière
EP4117668A4 (fr)	2023-12-06	Composition et méthode de traitement oral de la leucémie
EP4058029C0 (fr)	2025-03-26	Compositions multimodales et méthodes de traitement
EP4095090A4 (fr)	2025-01-01	Soufre modifié et sa méthode de préparation
EP4271370A4 (fr)	2024-12-04	Composition et méthode de traitement du cancer
EP3804759A4 (fr)	2022-07-20	Méthode de traitement et/ou de prévention de maladies liées à la regnase-1
EP4240755A4 (fr)	2024-12-18	Méthodes et compositions de classification et de traitement du cancer du poumon à petites cellules
EP3801585A4 (fr)	2022-03-16	Compositions et méthode de traitement et de prévention des complications de l'obésité
EP4228599A4 (fr)	2025-03-12	Méthodes de traitement de la dystonie cervicale
EP3684370A4 (fr)	2021-07-07	Composition et méthode de traitement de la dmla sèche (dégénérescence maculaire liée à l'âge)
EP4146181A4 (fr)	2024-10-09	Méthode de traitement du cancer du pancréas
EP4058005A4 (fr)	2023-05-24	Méthode de traitement de tumeurs rhabdoïdes
EP4232160A4 (fr)	2024-10-16	Compositions et méthodes de prévention et de traitement de coronavirus
EP4291163A4 (fr)	2025-01-01	Traitement de la myopie

Legal Events

Date	Code	Title	Description
2022-10-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: UNKNOWN
2022-10-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2022-12-16	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-12-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2023-01-18	17P	Request for examination filed	Effective date: 20221014
2023-01-18	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-12-06	A4	Supplementary search report drawn up and despatched	Effective date: 20231108
2023-12-06	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/02 20060101ALI20231102BHEP Ipc: A61K 45/06 20060101ALI20231102BHEP Ipc: A61K 31/522 20060101AFI20231102BHEP
2024-07-24	DAV	Request for validation of the european patent (deleted)
2024-07-24	DAX	Request for extension of the european patent (deleted)
2025-09-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2025-10-08	17Q	First examination report despatched	Effective date: 20250905